Better Health for All

Sana Biotechnology's core business is developing engineered cell medicines for potentially curative treatments for diseases like cancer, diabetes, and neurological disorders, aiming to repair and control genes or replace any cell in the body.

Their donor-derived islets have shown to be making insulin 6+ months after the first person was treated without immunosuppression, and preliminary 12-week clinical results for UP421 in type 1 diabetes demonstrated stable C-peptide production without immunosuppression. The company has no revenue from products with negative health outcomes. Sana is a science-driven company, investing in its proprietary hypoimmune platform and in vivo gene delivery technologies, with its entire R&D budget dedicated to health improvement.

Fair Pay & Worker Respect

The company's employee overall rating is 2.1 out of 5 stars, which is significantly below the industry average of 3.5 stars.

Only 15% of employees would recommend working at Sana Biotechnology to a friend, and 4% approve of the CEO. The compensation and benefits rating is 3.3 out of 5 stars, a decrease of 18% in the past 12 months. Work/life balance and culture & values are rated 2.2 out of 5 stars, while career opportunities are rated 2.0 out of 5 stars. Multiple employee reviews cite recurring layoffs, often with little notice or transparency, and allege poor leadership, lack of communication, and a dysfunctional C-suite.

Fair Trade & Ethical Sourcing

No specific, concrete evidence was found in the provided articles to assess Sana Biotechnology, Inc. against any of the KPIs for Fair Trade & Ethical Sourcing. Information regarding fair-trade certification, supplier audit frequency, forced or child labor incidents, supply chain traceability, remediation speed for violations, ethical clauses in supplier contracts, materials risk index, or supplier diversity spend was not explicitly stated.

The articles primarily discuss the company's internal Code of Business Conduct and Ethics, which applies to its own personnel and operations, rather than its supply chain or supplier contracts.

Honest & Fair Business

Sana Biotechnology, Inc. is facing a lawsuit alleging securities law violations.

The complaint claims the company issued materially false and/or misleading statements and/or failed to disclose information regarding its financial health and the prospects of its product candidates (SC291, SC379, and SG299). The lawsuit specifically alleges that Sana overstated its financial capacity to maintain operations and advance its product candidates. The alleged class period for these violations is from March 17, 2023, to November 4, 2024. The deadline for a lead plaintiff to register in the class action is May 20, 2025.

No War, No Weapons

Sana Biotechnology, Inc. reported no lobbying activities in 2024.

The provided articles do not contain any information regarding the company's revenue from arms or defense contracts, investment in dual-use technologies, sales to embargoed regimes, peacebuilding initiatives, or any policies related to conflict zones or weapons.

Respect for Cultures & Communities

No specific, concrete evidence was found in the provided articles for any of the KPIs related to 'Respect for Cultures & Communities' for Sana Biotechnology, Inc. The articles either explicitly state 'Not Available' for the relevant metrics

or provide information about an individual employee's past volunteer work and DEI involvement at other organizations, which does not constitute company-wide evidence for Sana Biotechnology, Inc.

Safe & Smart Tech

Sana holds ISO 27001, SOC 2, and GDPR compliance certifications, and requires sub-processors to hold additional certifications including ISO27017, ISO27018, PCI DSS, and CSA STAR.

All employees are required to take security training annually. Customer data at rest is encrypted with AES-128 and AES-256, and data in transit with TLS 1.2. The company implements preventative measures against unauthorized data use, including least privilege, role-based permissions, multi-factor authentication, password hashing, and vulnerability scanning. Sana's privacy policy allows users to request deletion and access to their data, with verification required. Multi-factor authentication is used for highly confidential data, and password validation and recovery techniques are in place. The company conducts annual third-party penetration testing and vulnerability scanning. Privacy by design and default are stated as essential considerations. 100% of critical user flows are covered by automated security testing. Data is anonymized within 30 calendar days of backup but stored indefinitely. The privacy policy mentions HIPAA compliance and other applicable laws, and GDPR compliance is explicitly stated.

Zero Waste & Sustainable Products

In 2023, Sana Biotechnology achieved a 68% recyclable waste rate.

The company has set waste reduction targets, including a 20% reduction in laboratory energy consumption by 2025, a 30% decrease in water usage by 2026, and an 85% recyclable waste target by 2027. The company had no waste disposal violations in the past three years. In 2023, Sana Biotechnology achieved a 22% decrease in water usage and a 14.2% reduction in laboratory energy consumption. The company sources 100% of its research materials from certified sustainable suppliers. Sana Biotechnology is ISO 14001 Certified.